An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and
An Australian subsidiary of Syncor has acquired Radpharm Scientific, distributor and manufacturer of diagnostic radiopharmaceuticals. Based in Canberra, Radpharm distributes its products to more than 160 nuclear medicine practices in Australia and exports to New Zealand, Singapore, Malaysia, Thailand, and Hong Kong. The acquisition gives Syncor a presence in Canberra along with its existing sites in Sydney, Perth, and Brisbane.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.